{
    "root": "3607d194-8f01-a643-e063-6394a90a1688",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "capecitabine",
    "value": "20250526",
    "ingredients": [
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE 112",
            "code": "X7XJ6RM9Q2",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "ANHYDROUS LACTOSE",
            "code": "3SY5LH9PMK",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "HYPROMELLOSE 2910 (5 MPA.S)",
            "code": "R75537T0T4",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "CAPECITABINE",
            "code": "6804DJ8Z9U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31348"
        }
    ],
    "indications": {
        "text": "capecitabine nucleoside metabolic inhibitor indicated : colorectal cancer \u2022 adjuvant treatment patients stage iii colon cancer single agent component combination chemotherapy regimen . ( 1.1 ) \u2022 perioperative treatment adults locally advanced rectal cancer component chemoradiotherapy . ( 1.1 ) \u2022 treatment patients unresectable metastatic colorectal cancer single agent component combination chemotherapy regimen . ( 1.1 ) breast cancer \u2022 treatment patients advanced metastatic breast cancer single agent anthracycline-or taxane-containing chemotherapy indicated . ( 1.2 ) \u2022 treatment patients advanced metastatic breast cancer combination docetaxel disease progression prior anthracycline-containing chemotherapy . ( 1.2 ) gastric , esophageal , gastroesophageal junction cancer \u2022 treatment adults unresectable metastatic gastric , esophageal , gastroesophageal junction cancer component combination chemotherapy regimen . ( 1.3 ) \u2022 treatment adults her2-overexpressing metastatic gastric gastroesophageal junction adenocarcinoma received prior treatment metastatic disease component combination regimen . ( 1.3 ) pancreatic cancer \u2022 adjuvant treatment adults pancreatic adenocarcinoma component combination chemotherapy regimen . ( 1.4 )",
        "doid_entities": [
            {
                "text": "colorectal cancer (DOID:9256)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9256"
            },
            {
                "text": "cancer (DOID:162)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_162"
            },
            {
                "text": "colon cancer (DOID:219)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_219"
            },
            {
                "text": "rectal cancer (DOID:1993)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1993"
            },
            {
                "text": "breast cancer (DOID:1612)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1612"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "gastroesophageal junction adenocarcinoma (DOID:4944)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4944"
            },
            {
                "text": "adenocarcinoma (DOID:299)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_299"
            },
            {
                "text": "pancreatic cancer (DOID:1793)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1793"
            },
            {
                "text": "pancreatic adenocarcinoma (DOID:4074)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4074"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "adjuvant treatment colon cancer \u2022 single agent : 1,250 mg/m 2 twice daily orally first 14 days 21-day cycle maximum 8 cycles . ( 2.1 ) combination oxaliplatin-containing regimens : 1,000 mg/m 2 orally twice daily first 14 days 21-day cycle maximum 8 cycles combination oxaliplatin 130 mg/m 2 administered intravenously day 1 cycle . ( 2.1 ) perioperative treatment rectal cancer \u2022 concomitant radiation therapy : 825 mg/m 2 orally twice daily ( 2.1 ) \u2022 without radiation therapy : 1,250 mg/m 2 orally twice daily ( 2.1 ) unresectable metastatic colorectal cancer : \u2022 single agent : 1,250 mg/m 2 twice daily orally first 14 days 21-day cycle disease progression unacceptable toxicity . ( 2.1 ) \u2022 combination oxaliplatin : 1,000 mg/m 2 orally twice daily first 14 days 21-day cycle disease progression unacceptable toxicity combination oxaliplatin 130 mg/m 2 administered intravenously day 1 cycle . ( 2.1 ) advanced metastatic breast cancer : \u2022 single agent : 1,000 mg/m 2 1,250 mg/m 2 twice daily orally first 14 days 21-day cycle disease progression unacceptable toxicity . ( 2.2 ) \u2022 combination docetaxel : 1,000 mg/m 2 1,250 mg/m 2 orally twice daily first 14 days 21-day cycle , disease progression unacceptable toxicity combination docetaxel 75 mg/m 2 administered intravenously day 1 cycle ( 2.2 ) unresectable metastatic gastric , esophageal , gastroesophageal junction cancer \u2022 625 mg/m 2 orally twice daily days 1 21 21-day cycle maximum 8 cycles combination platinum-containing chemotherapy . ( 2.3 ) \u2022 850 mg/m 2 1,000 mg/m 2 orally twice daily first 14 days 21-day cycle disease progression unacceptable toxicity combination oxaliplatin 130 mg/m 2 administered intravenously day 1 cycle . ( 2.3 ) her2-overexpressing metastatic adenocarcinoma gastroesophageal junction stomach \u2022 1,000 mg/m 2 orally twice daily first 14 days 21-day cycle disease progression unacceptable toxicity combination cisplatin trastuzumab . ( 2.3 ) pancreatic cancer \u2022 830 mg/m 2 orally twice daily first 21 days 28-day cycle maximum 6 cycles combination gemcitabine 1,000 mg/m 2 administered intravenously days 1 , 8 , 15 cycle . ( 2.4 ) refer sections 2.5 2.6 information related modifications renal impairment ( 2.5 2.6 ) .",
        "doid_entities": [
            {
                "text": "colon cancer (DOID:219)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_219"
            },
            {
                "text": "cancer (DOID:162)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_162"
            },
            {
                "text": "rectal cancer (DOID:1993)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1993"
            },
            {
                "text": "colorectal cancer (DOID:9256)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9256"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "breast cancer (DOID:1612)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1612"
            },
            {
                "text": "adenocarcinoma (DOID:299)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_299"
            },
            {
                "text": "pancreatic cancer (DOID:1793)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1793"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "capecitabine tablets usp , 150 mg light peach colored , capsule shaped , biconvex film coated tablets debossed \u2018 6 \u2019 one side \u2018 h \u2019 side . supplied follows : bottle 60 tablets ndc 68001-643-06 capecitabine tablets usp , 500 mg peach colored , oval shaped , biconvex film coated tablets deposited 3 \u2019 one side \u2018 h \u2019 side . supplied follows : bottle 120 tablets ndc 68001-644-07 storage handling store 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0fto 86\u00b0f ) [ usp controlled room temperature ] . keep tightly closed . capecitabine tablet usp hazardous . follow applicable special handling disposal procedures . 1",
    "adverseReactions": "capecitabine contraindicated patients history severe hypersensitivity reaction fluorouracil capecitabine [ ( 6.1 ) ] .",
    "indications_original": "Capecitabine is a nucleoside metabolic inhibitor indicated for: Colorectal Cancer \u2022\u00a0adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 ) \u2022\u00a0perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. ( 1.1 ) \u2022\u00a0treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 ) Breast Cancer \u2022\u00a0treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline-or taxane-containing chemotherapy is not indicated. ( 1.2 ) \u2022\u00a0treatment of patients with advanced or metastatic breast cancer in combination with docetaxel after disease progression on prior anthracycline-containing chemotherapy. ( 1.2 ) Gastric, Esophageal, or Gastroesophageal Junction Cancer \u2022\u00a0treatment of adults with unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer as a component of a combination chemotherapy regimen. ( 1.3 ) \u2022\u00a0treatment of adults with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen. ( 1.3 ) Pancreatic Cancer \u2022\u00a0adjuvant treatment of adults with pancreatic adenocarcinoma as a component of a combination chemotherapy regimen. ( 1.4 )",
    "contraindications_original": "Adjuvant Treatment of Colon Cancer \u2022\u00a0Single agent: 1,250 mg/m 2 twice daily orally for the first 14 days of each 21-day cycle for a maximum of 8 cycles. ( 2.1 ) In combination with Oxaliplatin-Containing Regimens: 1,000 mg/m 2 orally twice daily for the first 14 days of each 21-day cycle for a maximum of 8 cycles in combination with oxaliplatin 130 mg/m 2 administered intravenously on day 1 of each cycle. ( 2.1 ) Perioperative Treatment of Rectal Cancer \u2022\u00a0With Concomitant Radiation Therapy: 825 mg/m 2 orally twice daily ( 2.1 ) \u2022\u00a0Without Radiation Therapy: 1,250 mg/m 2 orally twice daily ( 2.1 ) Unresectable or Metastatic Colorectal Cancer: \u2022\u00a0Single agent: 1,250 mg/m 2 twice daily orally for the first 14 days of each 21-day cycle until disease progression or unacceptable toxicity. ( 2.1 ) \u2022\u00a0In Combination with Oxaliplatin: 1,000 mg/m 2 orally twice daily for the first 14 days of each 21-day cycle until disease progression or unacceptable toxicity in combination with oxaliplatin 130 mg/m 2 administered intravenously on day 1 of each cycle. ( 2.1 ) Advanced or Metastatic Breast Cancer: \u2022\u00a0Single agent: 1,000 mg/m 2 or 1,250 mg/m 2 twice daily orally for the first 14 days of each 21-day cycle until disease progression or unacceptable toxicity. ( 2.2 ) \u2022\u00a0In combination with docetaxel: 1,000 mg/m 2 or 1,250 mg/m 2 orally twice daily for the first 14 days of a 21-day cycle, until disease progression or unacceptable toxicity in combination with docetaxel at 75 mg/m 2 administered intravenously on day 1 of each cycle ( 2.2 ) Unresectable or Metastatic Gastric, Esophageal, or Gastroesophageal Junction Cancer \u2022\u00a0625 mg/m 2 orally twice daily on days 1 to 21 of each 21-day cycle for a maximum of 8 cycles in combination with platinum-containing chemotherapy. ( 2.3 ) OR \u2022\u00a0850 mg/m 2 or 1,000 mg/m 2 orally twice daily for the first 14 days of each 21-day cycle until disease progression or unacceptable toxicity in combination with oxaliplatin 130 mg/m 2 administered intravenously on day 1 of each cycle. ( 2.3 ) HER2-overexpressing metastatic adenocarcinoma of the gastroesophageal junction or stomach \u2022\u00a01,000 mg/m 2 orally twice daily for the first 14 days of each 21-day cycle until disease progression or unacceptable toxicity in combination with cisplatin and trastuzumab. ( 2.3 ) Pancreatic cancer \u2022\u00a0830 mg/m 2 orally twice daily for the first 21 days of each 28-day cycle for maximum of 6 cycles in combination with gemcitabine 1,000 mg/m 2 administered intravenously on days 1, 8, and 15 of each cycle. ( 2.4 ) Refer to Sections 2.5 and 2.6 for information related to dosage modifications for adverse reactions and renal impairment ( 2.5 and 2.6 ).",
    "warningsAndPrecautions_original": "Capecitabine tablets USP, 150 mg are light peach colored, capsule shaped, biconvex film coated tablets debossed with \u20186\u2019 on one side and \u2018H\u2019 on the other side. They are supplied as follows: \n    Bottle of 60 tablets\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0NDC 68001-643-06 \n    Capecitabine tablets USP, 500 mg are peach colored, oval shaped, biconvex film coated tablets deposited with 3\u2019 on one side and \u2018H\u2019 on the other side. They are supplied as follows: \n    Bottle of 120 tablets\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 NDC 68001-644-07 \n  \n                     Storage and Handling\n                       Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted to 15\u00b0C to 30\u00b0C (59\u00b0Fto 86\u00b0F)\n \n  [see USP Controlled Room Temperature].KEEP TIGHTLY CLOSED. \n    Capecitabine tablet USP is a hazardous drug. Follow applicable special handling and disposal procedures.\n \n  1",
    "adverseReactions_original": "Capecitabine is contraindicated in patients with history of severe hypersensitivity reaction to fluorouracil or capecitabine\n \n  [see\n  \n   Adverse Reactions (6.1)].",
    "drug": [
        {
            "name": "capecitabine",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31348"
        }
    ]
}